Envista to acquire Osteogenics Biomedical for ~$30M annual sales; closes Q3

Envista Holdings Corp

Definitive agreement to acquire Osteogenics Biomedical, Allotech, OBI Biologics (Cytoplast brand).
Osteogenics has ~$30M annual sales; leader in regenerative solutions for dental bone grafting.
Transaction subject to customary regulatory approvals; expected close in Q3 2022.
No financing condition or shareholder vote required; funded from existing resources.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.